Browsing by Subject "Histopathology"

Article

Angiogenesis in cancer of unknown primary: Clinicopathological study of CD34, VEGF and TSP-1

Karavasilis, V.; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Tsanou, E.; Kitsou, E.; Kalofonos, H. P.; Fountzilas, George; Fotsis, T.; Pavlidis, Nicholas (2005)

Background: Cancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge ...

Article

Brain metastasis of unknown primary: A diagnostic and therapeutic dilemma

Polyzoidis, K. S.; Miliaras, G.; Pavlidis, Nicholas (2005)

The diagnosis of a brain metastasis is usually made during the routine follow up examinations of patients with known cancer, who are under the care of oncology departments. The involvement of the neurosurgeon depends on ...

Article

Cancer of unknown primary during pregnancy: An exceptionally rare coexistence

Pavlidis, Nicholas; Peccatori, Fedro A.; Lofts, F.; Greco, F. A. (2015)

Background: Cancer in pregnancy is a rare disease with breast cancer, cervical cancer, melanoma and Hodgkin's disease to be the most commonly diagnosed malignancies during gestation. Cancer of unknown primary (CUP) is a ...

Article

Cancer of unknown primary site

Pavlidis, Nicholas; Pentheroudakis, George (2012)

Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5 of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease with early dissemination. ...

Article

Cancer of unknown primary site: 20 questions to be answered

Pavlidis, Nicholas; Pentheroudakis, George (2010)

Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic ...

Article

Cancer of unknown primary: Biological and clinical characteristics

Pavlidis, Nicholas (2003)

Article

Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Pavlidis, Nicholas; Briassoulis, E. Ch; Pentheroudakis, George (2010)

Article

Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up

Briassoulis, E. Ch; Pavlidis, Nicholas; Felip, E. (2008)

Article

Cancers of unknown primary site: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Briassoulis, E. Ch; Pavlidis, Nicholas (2007)

Article

Carcinoma of unknown primary (CUP)

Pavlidis, Nicholas; Fizazi, K. (2009)

Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...

Article

Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma

Karavasilis, V.; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Tsanou, E.; Kitsou, E.; Pavlidis, Nicholas (2006)

The aim of the study was to investigate angiogenesis in patients with advanced-stage ovarian carcinoma. We used paraffin-embedded tumor tissues from 33 patients diagnosed with FIGO III ovarian cancer who had optimal surgery ...

Article

Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors

Zagorianakou, N.; Stefanou, D. G.; Makrydimas, G.; Zagorianakou, P.; Briassoulis, E. Ch; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2006)

Metallothioneins (MTs) are a family of cystein-rich metal-binding proteins, which are expressed in normal cells during fetal and postnatal life but also in a variety of human neoplasms. MT expression in human tumors has ...

Article

Cutaneous lymphocytic vasculopathy in lymphoproliferative disorders-a paraneoplastic lymphocytic vasculitis of the skin

Pavlidis, Nicholas; Klouvas, G. D.; Tsokos, M.; Bai, M. C.; Moutsopoulos, H. M. (1995)

In this report the histopathology and the natural history of cutaneous lymphocytic vasculopathy (lymphocytic vasculitis) in patients with lymphoproliferative diseases, is described. Between January 1986 and June 1992,116 ...

Article

Diagnostic and therapeutic management of cancer of an unknown primary

Pavlidis, Nicholas; Briassoulis, E. Ch; Hainsworth, J.; Greco, F. A. (2003)

Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all malignant neoplasms and is therefore one of the 10 most frequent cancer diagnoses in man. Patients with CUP present with metastatic disease ...

Article

Donor-derived breast cancer in a bone marrow transplantation recipient

Golfinopoulos, Vassilis; Pentheroudakis, George; Kamakari, S.; Metaxa-Mariatou, V.; Pavlidis, Nicholas (2009)

We present the case of a young lady who had been treated for acute myelocytic leukemia at the age of 14 by means of allogeneic bone marrow transplantation, the donor being her sister. At the age of 28 she underwent modified ...

Article

Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer

Fountzilas, George; Papadimitriou, C.; Aravantinos, Gerasimos; Nikolaides, C.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Kalofonos, H. P.; Economopoulos, T.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)

Dose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. ...

Article

Endobronchial metastases secondary to solid tumors: Report of eight cases and review of the literature

Katsimbri, P. P.; Bamias, A. T.; Froudarakis, M. E.; Peponis, I. A.; Constantopoulos, S. H.; Pavlidis, Nicholas (2000)

Endobronchial metastases (EBM) secondaries to extrapulmonary solid malignant tumors are rare. Breast, colon and renal adenocarcinomas are the most frequent tumors associated with EBM. Since 1990 we have treated eight ...

Article

ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)

Felip, E.; Stahel, R. A.; Pavlidis, Nicholas (2005)

Article

ESMO minimum clinical recommendations for diagnosis, treatment and follow-up pancreatic cancer

Herrmann, R.; Jost, Lorenz M.; Pavlidis, Nicholas (2005)

Article

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)

Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...